BMS-986020(溶血磷脂酸受体拮抗剂)治疗特发性肺纤维化的随机、双盲、安慰剂对照2期试验
IM136003是一项2期、平行组、多中心、随机、双盲、安慰剂对照试验,纳入143例IPF成人患者(FVC 45%-90%,DLCO 30%-80%),随机接受安慰剂或BMS-986020 600 mg每日一次或每日两次治疗26周。主要终点为基线至第26周FVC变化速率。BMS-986020 600 mg每日两次组FVC下降速率显著慢于安慰剂组(-0.042 L,95%CI -0.106至-0.022 vs -0.134 L,95%CI -0.201至-0.068,P=0.049)。两种BMS-986020方案均观察到剂量相关的肝酶升高。研究因解盲后确定与BMS-986020相关的3例胆囊炎而提前终止。
要点
- 在IPF成人患者中,BMS-986020 600 mg每日两次治疗26周较安慰剂显著减缓FVC下降速率(-0.042 L vs -0.134 L,P=0.049)。
- BMS-986020 600 mg每日一次和每日两次两种方案均观察到剂量相关的肝酶升高。
- 研究因解盲后判定与BMS-986020相关的3例胆囊炎而提前终止。
- 143例随机患者中108例完成26周给药阶段,35例提前终止。
适用人群与场景
- 成人特发性肺纤维化患者,FVC 45%-90%,一氧化碳弥散量30%-80%。
处置流程与药物剂量
- BMS-986020 600 mg每日一次或每日两次口服,疗程26周(研究方案给药,非通用推荐)。
红旗征与不能漏的情况
- 肝酶升高:两种BMS-986020方案均观察到剂量相关的肝酶升高。
- 胆囊炎:3例胆囊炎经解盲后判定与BMS-986020相关,研究因此提前终止。
研究设计与关键结果
- IM136003为2期、平行组、多中心、随机、双盲、安慰剂对照试验,143例IPF患者随机分为安慰剂组(n=47)、BMS-986020 600 mg每日一次组(n=48)和600 mg每日两次组(n=48),108例完成26周给药阶段,35例提前终止。
- 主要终点基线至第26周FVC变化速率:BMS-986020 600 mg每日两次组为-0.042 L(95%CI -0.106至-0.022),安慰剂组为-0.134 L(95%CI -0.201至-0.068),组间比较P=0.049。
- 两种BMS-986020治疗组均观察到剂量相关的肝酶升高。
- 研究因解盲后确定与BMS-986020相关的3例胆囊炎而提前终止。
证据类型、等级与局限
- 证据类型:2期、随机、双盲、安慰剂对照试验。
- 局限:研究因3例与BMS-986020相关的胆囊炎而提前终止。
对床旁实践的改变
- 作者认为,BMS-986020 600 mg每日两次治疗26周较安慰剂显著减缓IPF患者FVC下降速率。
- 使用BMS-986020时需注意两种方案均伴肝酶升高,以及3例与药物相关的胆囊炎导致研究提前终止。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「诊断标准与关键阈值」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
BACKGROUND: Idiopathic pulmonary fibrosis (IPF) causes irreversible loss of lung function. The lysophosphatidic acid receptor 1 (LPA1) pathway is implicated in IPF etiology. Safety and efficacy of BMS-986020, a high-affinity LPA1 antagonist, was assessed vs placebo in a phase 2 study in patients with IPF.
METHODS: IM136003 was a phase 2, parallel-arm, multicenter, randomized, double-blind, placebo-controlled trial. Adults with IPF (FVC, 45%-90%; diffusing capacity for carbon monoxide, 30%-80%) were randomized to receive placebo or 600 mg BMS-986020 (once daily [qd] or bid) for 26 weeks. The primary end point was rate of change in FVC from baseline to week 26.
RESULTS: Of 143 randomized patients, 108 completed the 26-week dosing phase. Thirty-five patients discontinued prematurely. Patient baseline characteristics were similar between treatment groups (placebo: n = 47; 600 mg qd: n = 48; 600 mg bid: n = 48). Patients treated with BMS-986020 bid experienced a significantly slower rate of decline in FVC vs placebo (-0.042 L; 95% CI, -0.106 to -0.022 vs -0.134 L; 95% CI, -0.201 to -0.068, respectively; P = .049). Dose-related elevations in hepatic enzymes were observed in both BMS-986020 treatment groups. The study was terminated early because of three cases of cholecystitis that were determined to be related to BMS-986020 after unblinding.
CONCLUSIONS: BMS-986020 600 mg bid treatment for 26 weeks vs placebo significantly slowed the rate of FVC decline. Both regimens of BMS-986020 were associated with elevations in hepatic enzymes.
TRIAL REGISTRY: ClinicalTrials.gov; No.: NCT01766817; URL: www.clinicaltrials.gov.
参考来源
- Palmer SM, Snyder L, Todd JL, et al. Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis. Chest. 2018. PMID: 30201408. doi:10.1016/j.chest.2018.08.1058
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。